Amyloidosis Clinical Trials in Beijing, Beijing Municipality (12 Recruiting)

Showing 1–12 of 12 trials

A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA)

Amyloidosis

Sinocelltech Ltd.90 enrolled1 locationNCT07388602

Recruiting

Phase 1Phase 2

Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis Patients

Systemic Light Chain Amyloidosis

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.70 enrolled23 locationsNCT07266116

Recruiting

Phase 2

Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain Amyloidosis

Primary Light-Chain Amyloidosis

Keymed Biosciences Co.Ltd90 enrolled2 locationsNCT07039578

Recruiting

Phase 2

Daratumumab Combined With Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis With Translocation (11;14)

Light Chain (AL) Amyloidosis

Peking Union Medical College Hospital36 enrolled1 locationNCT06629818

Recruiting

Phase 2

Teclistamab in Previously Treated AL Amyloidosis

AL Amyloidosis

Peking Union Medical College Hospital30 enrolled1 locationNCT06935162

Recruiting

Not Applicable

Exploratory Clinical Study on the Safety and Efficacy of Targeted BCMA Autologous CART Cell Injection in Subjects With Recurrent/Refractory Light Chain Amyloidosis

Light Chain Amyloidosis

Beijing Boren Hospital30 enrolled1 locationNCT06983951

Recruiting

Not Applicable

Prospective Study of Teclistamab in the Treatment of Systemic AL Amyloidosis

AL Amyloidosis

Peking University People's Hospital20 enrolled2 locationsNCT06699394

Recruiting

Phase 2

Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis

Systemic Amyloidosis

Jin Lu, MD40 enrolled1 locationNCT06342466

Recruiting

Phase 1Phase 2

A Phase I/IIa，Open-label, Single Ascending Dose and Dose-expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of YOLT-201 in Patients With Transthyretin Amyloidosis Polyneuropathy (ATTR-PN) or Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Transthyretin Amyloidosis PolyneuropathyTransthyrexin Amyloidosis Cardiomyopathy

YolTech Therapeutics Co., Ltd31 enrolled3 locationsNCT06539208

Amyloidosis Clinical Trials in Beijing, Beijing Municipality

Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

Optimize First-line Treatment for AL Amyloidosis With t (11; 14)

Rapid dFLC Response Predict CHR in AL Amyloidosis

A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA)

Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis Patients

Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain Amyloidosis

Daratumumab Combined With Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis With Translocation (11;14)

Teclistamab in Previously Treated AL Amyloidosis

Exploratory Clinical Study on the Safety and Efficacy of Targeted BCMA Autologous CART Cell Injection in Subjects With Recurrent/Refractory Light Chain Amyloidosis

Prospective Study of Teclistamab in the Treatment of Systemic AL Amyloidosis

Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis

A Phase I/IIa，Open-label, Single Ascending Dose and Dose-expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of YOLT-201 in Patients With Transthyretin Amyloidosis Polyneuropathy (ATTR-PN) or Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)